ESC 2019 Compared to a three-hour protocol, a one-hour hs-troponin protocol reduced length of stay and was safe up to 30 days for patients with suspected ACS.
ESC 2019 Implementation of a genotype-guided strategy for the selection of clopidogrel or more potent P2Y12 inhibitors was as good as standard treatment for net clinical benefit and reduced bleeding.
ESC 2019 Comparison of prasugrel with ticagrelor showed that prasugrel was superior in reducing death, MI and stroke at one year in ACS patients with and without ST-segment elevation.
ESC 2019 Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduced ischemic endpoints as compared with ticagrelor, without an increased bleeding risk.
ESC 2019 In patients with suspected ACS, adoption of an early rule-out pathway for MI using hs-troponin reduced the length of stay, increased proportion of patients discharged by emergency department and was safe.
CLARIFY registry data suggest that beta-blocker use was only associated with lower 5-year mortality in patients enrolled in the year following in MI. Use of calcium antagonists did not impact mortality.
An analysis of the COMPASS trial in patients with GFR ≥60 or <60 mL/min showed consistent treatment benefit of the combination of rivaroxaban 2.5 mg bd plus aspirin, vs aspirin alone.
The FDA has approved alirocumab to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established CVD, based on ODYSSEY OUTCOMES data.
No interaction was observed between diabetes status, guided DAPT de-escalation therapy vs. control therapy and outcomes in ACS patients after PCI.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
A prespecified analysis of the ODYSSEY OUTCOMES trial showed a higher incidence of MACE and death in ACS patients with polyvascular disease and alirocumab treatment resulted in a large absolute benefit in these patients.
ACC 2019 Dr. John Alexander summarizes the main findings of the AUGUSTUS trial, in which apixaban yielded better results than warfarin, and those not on aspirin did better than those taking aspirin, in patients with AF and a recent ACS/PCI.